Humatica Ltd. was retained to advise the Riverside Company on its investment in Alter Pharma, a Belgian pharmaceutical group. Alter Pharma distributes EU-sourced pharmaceutical products to wholesalers pharmacies and hospitals. It also develops and reformulates generic pharmaceuticals using GMP approved third-party manufacturers, and sells them internationally through partnerships
Humatica provided organisational due diligence services for this transaction.
To view press release: Humatica Advisor to Riverside for AlterPharma
Humatica has once again been short-listed for Actum’s 2026 Value Creation Award in the People & Organisational Strategy category. This recognition reflects Humatica’s 23‑year commitment…
Read more
Humatica is once again shortlisted for Real Deals’ prestigious Private Equity Awards 2026 in the “Value Creation Adviser of the Year” category. This recognition underscores…
Read more
London, January 2026 – Humatica, an award winning leader in organizational transformation for Private Equity, has been officially accredited as a Great Place to Work…
Read more